| Literature DB >> 23778141 |
Philip J Stephens1, Helen R Davies, Yoshitsugu Mitani, Peter Van Loo, Adam Shlien, Patrick S Tarpey, Elli Papaemmanuil, Angela Cheverton, Graham R Bignell, Adam P Butler, John Gamble, Stephen Gamble, Claire Hardy, Jonathan Hinton, Mingming Jia, Alagu Jayakumar, David Jones, Calli Latimer, Stuart McLaren, David J McBride, Andrew Menzies, Laura Mudie, Mark Maddison, Keiran Raine, Serena Nik-Zainal, Sarah O'Meara, Jon W Teague, Ignacio Varela, David C Wedge, Ian Whitmore, Scott M Lippman, Ultan McDermott, Michael R Stratton, Peter J Campbell, Adel K El-Naggar, P Andrew Futreal.
Abstract
Adenoid cystic carcinoma (ACC) is a rare malignancy that can occur in multiple organ sites and is primarily found in the salivary gland. While the identification of recurrent fusions of the MYB-NFIB genes have begun to shed light on the molecular underpinnings, little else is known about the molecular genetics of this frequently fatal cancer. We have undertaken exome sequencing in a series of 24 ACC to further delineate the genetics of the disease. We identified multiple mutated genes that, combined, implicate chromatin deregulation in half of cases. Further, mutations were identified in known cancer genes, including PIK3CA, ATM, CDKN2A, SF3B1, SUFU, TSC1, and CYLD. Mutations in NOTCH1/2 were identified in 3 cases, and we identify the negative NOTCH signaling regulator, SPEN, as a new cancer gene in ACC with mutations in 5 cases. Finally, the identification of 3 likely activating mutations in the tyrosine kinase receptor FGFR2, analogous to those reported in ovarian and endometrial carcinoma, point to potential therapeutic avenues for a subset of cases.Entities:
Mesh：
Year: 2013 PMID： 23778141 PMCID： PMC3999050 DOI： 10.1172/JCI67201
Source DB: PubMed Journal: J Clin Invest ISSN： 0021-9738 Impact factor: 14.808